PULSAR (パーソナライズド・ウルトラ・フラクション・ステレオタクシー・アダプティブ・放射線療法) の使用は,小児転移性メラノーマの治療において,免疫チェックポイント阻害による統合として用いられる
関連する実験動画
Updated: Sep 10, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
539
Kyra L McCarty1, Tanya Watt2, Tu D Dan3
1Division of Pediatric Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, USA. kyra.mccarty@duke.edu.
Radiation oncology (London, England)
|August 21, 2025
まとめ
このケーススタディは,プログラムされた細胞死 (PD-1) 免疫療法とパーソナライズされた超分断型ステレオタクシー適応放射線療法 (PULSAR) の組み合わせが,小児転移性メラノーマを効果的に治療することを示しています. この併用療法により,再発または耐性疾患の患者に有意な腫瘍応答と進行状態が達成されました.
科学分野:
- 腫瘍学
- 免疫療法
- 放射線腫瘍学
背景:
- 小児の転移性メラノーマ,特に頭頸部では,治療に重大な課題があります.
- 手術および初期免疫療法 (抗PD-1および抗CTLA-4) を含む標準療法は,攻撃的な疾患では不十分である可能性があります.
- 小児患者の転移性または再発性メラノーマは,新しい治療戦略を必要とします.
研究 の 目的:
- 新種の併用療法で治療された広範囲の小児転移性メラノーマの症例を報告する.
- パーソナライズされた超分断型ステレオタクシー適応放射線療法 (PULSAR) と組み合わせた抗プログラム細胞死 (PD-1) 抑制の有効性を評価する.
- 耐性小児メラノーマの管理における免疫療法と放射線療法の相乗効果を評価する.
主な方法:
- 患者は手術で脱毛し,その後 連続治療と併用治療を受けた.
- 最初の治療は,ダブルチェックポイント阻害 (抗PD-1および抗CTLA-4) 免疫療法であり,その後,異なる抗PD-1剤とチロシンキナーゼ阻害剤を併用した.
- 強化療法と救済療法では,免疫療法と共にパーソナライズされた超分断型ステレオタキシ性適応放射線療法 (PULSAR) を使用した.
主要な成果:
- 患者さんは,ダブルチェックポイントブロックで初期疾患の進行を経験しましたが,抗PD-1免疫療法とPULSARの組み合わせに顕著な反応を示しました.
- この組み合わせは,以前の大規模な病気の部位で局所的な進行がなく,1年間の進行フリー状態を達成しました.
- PULSARとPD-1抗免疫療法の継続により,別の進行部位でさらに6ヶ月間進行症のない状態となった.
結論:
- 抗PD-1 免疫療法とPULSARの併用療法が小児転移性メラノーマの治療に有効であることが示されています.
- このアプローチは,再発性または耐性疾患の患者に対して,相乗効果を発揮します.
- PULSARは,小児性メラノーマの全身免疫療法と併用して有効な整合および救済局所療法であることを示唆しています.
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

